Zacks Investment Research
25 Jun 2026, 13:46 UTC · 2h ago
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
25 Jun 2026, 13:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AbCellera Biologics entered a preclinical research collaboration with Jazz Pharmaceuticals to develop T-cell-engaging multispecific antibodies for GI cancers and solid tumors. — The partnership provides significant potential revenue via $56 million in upfront payments and up to $792 million in future milestone payments per program.
+0.60AbCellera Biologics is expected to report a quarterly revenue decline of 55.5% and a quarterly loss of $0.17 per share. — Significant year-over-year revenue contraction and continued losses indicate fundamental financial weakness.
-0.40AbCellera Biologics shares rose 7.1% in the last trading session to close at $6.03. — Short-term price action reflects positive sentiment regarding the Jazz Pharmaceuticals deal but lacks long-term fundamental revision.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
Shares rallied 7.1% following a preclinical research collaboration deal with Jazz Pharmaceuticals.
The stock finished the last trading session 1.5% higher.
[mutual] AbCellera and Jazz Pharmaceuticals entered a preclinical research collaboration deal to develop multispecific antibodies.
[a_to_b] Jazz Pharmaceuticals is paying AbCellera upfront payments and milestone fees for research programs.
[mutual] Both companies are identified as members of the Zacks Medical - Biomedical and Genetics industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
16h ago
